Cancer Immunotherapy represents a portfolio of approaches aimed at deploying the immune system against tumor targets in vivo.  There is a growing body of scientific and clinical evidence that these approaches are yielding clinically-actionable strategies for cancer treatment.

Biofluid Biopsies represents the harvest of circulating biomarkers to monitor progression of disease especially in cancer.  The minimally-invasive means of capture of circulating-free DNA (cfDNA), circulating tumor cells (CTCs), circulating proteins and circulating extracellular vesicles (EVs) represents a new paradigm for longitudinal monitoring of disease and therapy progression.

Cancer Immunotherapy & Biofluid Biopsies 2016 brings together the key opinion leaders in the immunotherapy and tumor immunology fields to address the most up-to-date strategies for immune therapy and means by which immunotherapies may be rationally-combined with more traditional anti-cancer therapeutics.  This field is converging with biofluid biopsies/liquid biopsies and therefore this conference brings together these two disciplines as they are co-evolving.

This conference also addresses biomarkers and companion diagnostics (CDx) which can be utilized to "target patient populations" suitable for immunotherapies.

Presentations from researchers and clinician-scientists at this conference discuss the most recent themes and clinical data.